Wow! Reolysin Works

[Guest guest]

Transmitted by CNW Group on : June 5, 2008 11:08

Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II

Clinical Trial Investigating REOLYSIN® in Combination with

Paclitaxel and Carboplatin

CALGARY, June 5 /CNW/ - Oncolytics Biotech Inc.

( " Oncolytics " ) (TSX:ONC,

NASDAQ:ONCY) announced today that that it has started patient

enrolment in a

Phase II clinical trial using intravenous administration of REOLYSIN

® in

combination with paclitaxel and carboplatin in patients with advanced

head and

neck cancers. The principal investigator is Dr. Harrington of

The

Institute of Cancer Research and The Royal Marsden NHS Foundation

Trust.

This trial is a 14-patient, single arm, open-label, dose-

targeted,

non-randomized trial of REOLYSIN® given intravenously in

combination with a

standard dosage of paclitaxel and carboplatin. Eligible patients

include those

with advanced or metastatic head and neck cancers that are refractory

to

standard therapy or for which no curative standard therapy exists.

The primary

objective of the Phase II trial is to measure tumour responses and

duration of

response, and to describe any evidence of antitumour activity. The

secondary

objective is to determine the safety and tolerability of REOLYSIN®

when

administered in combination with paclitaxel and carboplatin to

patients with

advanced or metastatic head and neck cancer.